Metraipolis › archive › dc_db306945982b
Comprehensive immunoprofiling and systematic adjuvant comparisons for identifying suitable vaccine: Adjuvant pairings — Europe PMC PMID:37341528
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37341528
- DOI
- 10.1080/21645515.2023.2223503
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T12:29:26.662Z
- SHA-256 of the archived text
f0f655f1247c52195c8ef22861686f58fcc382b610358da9d4c0939ac5010038- Stable URL of this page
https://metraipolis.com/documento/dc_db306945982b
How to cite
Comprehensive immunoprofiling and systematic adjuvant comparisons for identifying suitable vaccine: Adjuvant pairings — Europe PMC PMID:37341528 — Europe PMC (en), https://europepmc.org/article/MED/37341528 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_db306945982b (Metraipolis archive dc_db306945982b, sha256 f0f655f1247c52195c8ef22861686f58fcc382b610358da9d4c0939ac5010038)
BibTeX
@misc{dcdb306945982b,
title = {Comprehensive immunoprofiling and systematic adjuvant comparisons for identifying suitable vaccine: Adjuvant pairings — Europe PMC PMID:37341528},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37341528},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_db306945982b; sha256 f0f655f1247c52195c8ef22861686f58fcc382b610358da9d4c0939ac5010038},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37341528. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Adjuvants are critical components of vaccines that enhance the host immune response to the vaccine antigen, however, only a small number of adjuvants are used in vaccines approved for human use. This is in part due to the slow process of novel adjuvants advancing from preclinical models to human studies, and modest mechanistic insights obtained using standard immunological methods to justify selection of a particular adjuvant for clinical evaluation. Here, we discuss several aspects of current adjuvant research and strategies to better assess the complex pathways triggered by adjuvant candidates that can increase adjuvanticity and vaccine efficacy while minimizing reactogenicity. We propose a more systematic use of broad immunoprofiling, coupled with data integration using computational and mathematical modeling. This comprehensive evaluation of the host immune response will facilitate the selection of the most appropriate adjuvant for a vaccine, ultimately leading to the expeditious evaluation of novel adjuvants for vaccines against emerging infectious diseases, which will prove especially valuable during a pandemic where speed is of the essence when developing vaccines. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: Human vaccines & immunotherapeutics, 2023 (prima pubblicazione 2023-08-01). Identificativi: PMID 37341528 · PMCID PMC10286686 · DOI 10.1080/21645515.2023.2223503. Parole chiave degli autori: Adjuvant; Reactogenicity; Immunoprofiling; Immunostimulators. Descrittori MeSH principali: Vaccines. Pagina: https://europepmc.org/article/MED/37341528 — https://doi.org/10.1080/21645515.2023.2223503. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T12:01:43.340Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.